Vor Biopharma Inc. Stock-Based Compensation
Vor Biopharma Inc. (VOR) reported Stock-Based Compensation of $18.27 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-11
- Vor Biopharma Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $9.40M, a 409.71% increase year-over-year.
- Vor Biopharma Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $8.87M, a 358.87% increase year-over-year.
- Vor Biopharma Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $7.11M, a 315.80% increase year-over-year.
- Vor Biopharma Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $8.03M, a 254.64% increase year-over-year.
- Vor Biopharma Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $18.91M, a 92.06% increase from fiscal 2024.
- Vor Biopharma Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $9.85M, a 26.31% decline from fiscal 2023.
- Vor Biopharma Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $13.36M, a 24.94% increase from fiscal 2022.
- Vor Biopharma Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $10.70M, a 147.86% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $18.27M 10-Q · filed 2026-08-11 | $25.38M derived: sum of 3 quarters · filed 2026-08-11 | $33.40M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $8.87M 10-Q · filed 2026-05-13 | $15.98M derived: sum of 2 quarters · filed 2026-05-13 | $24.00M derived: sum of 3 quarters · filed 2026-05-13 | $25.85M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $7.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $15.13M derived: sum of 2 quarters · filed 2026-03-30 | $16.98M derived: sum of 3 quarters · filed 2026-08-11 | $18.91M 10-K · filed 2026-03-30 |
| 2025-09-30 | $8.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $9.87M derived: sum of 2 quarters · filed 2026-08-11 | $11.81M 10-Q · filed 2025-11-13 | $13.52M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $1.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $3.78M 10-Q · filed 2026-08-11 | $5.49M derived: sum of 3 quarters · filed 2026-08-11 | $7.75M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $1.93M 10-Q · filed 2026-05-13 | $3.64M derived: sum of 2 quarters · filed 2026-05-13 | $5.91M derived: sum of 3 quarters · filed 2026-05-13 | $8.70M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $1.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $3.97M derived: sum of 2 quarters · filed 2026-03-30 | $6.77M derived: sum of 3 quarters · filed 2026-03-30 | $9.85M 10-K · filed 2026-03-30 |
| 2024-09-30 | $2.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $5.06M derived: sum of 2 quarters · filed 2025-11-13 | $8.14M 10-Q · filed 2025-11-13 | $10.03M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $2.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $5.87M 10-Q · filed 2025-08-12 | $7.77M derived: sum of 3 quarters · filed 2025-08-12 | $10.93M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $3.08M 10-Q · filed 2025-05-14 | $4.97M derived: sum of 2 quarters · filed 2025-05-14 | $8.14M derived: sum of 3 quarters · filed 2025-05-14 | $12.38M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $1.89M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $5.06M derived: sum of 2 quarters · filed 2025-03-20 | $9.29M derived: sum of 3 quarters · filed 2025-03-20 | $13.36M 10-K · filed 2025-03-20 |
| 2023-09-30 | $3.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $7.40M derived: sum of 2 quarters · filed 2024-11-07 | $11.47M 10-Q · filed 2024-11-07 | $15.35M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $4.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $8.31M 10-Q · filed 2024-08-08 | $12.19M derived: sum of 3 quarters · filed 2024-08-08 | $15.51M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $4.07M 10-Q · filed 2024-05-09 | $7.95M derived: sum of 2 quarters · filed 2024-05-09 | $11.28M derived: sum of 3 quarters · filed 2024-05-09 | $13.02M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $3.88M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $7.21M derived: sum of 2 quarters · filed 2024-03-20 | $8.95M derived: sum of 3 quarters · filed 2024-03-20 | $10.70M 10-K · filed 2024-03-20 |
| 2022-09-30 | $3.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $5.07M derived: sum of 2 quarters · filed 2023-11-07 | $6.82M 10-Q · filed 2023-11-07 | $8.02M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $1.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $3.49M 10-Q · filed 2023-08-10 | $4.69M derived: sum of 3 quarters · filed 2023-08-10 | $5.84M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $1.75M 10-Q · filed 2023-05-11 | $2.95M derived: sum of 2 quarters · filed 2023-05-11 | $4.10M derived: sum of 3 quarters · filed 2023-05-11 | $5.17M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $2.36M derived: sum of 2 quarters · filed 2023-03-23 | $3.42M derived: sum of 3 quarters · filed 2023-03-23 | $4.32M 10-K · filed 2023-03-23 |
| 2021-09-30 | $1.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $2.22M derived: sum of 2 quarters · filed 2022-11-10 | $3.11M 10-Q · filed 2022-11-10 | $3.71M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $1.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $1.96M 10-Q · filed 2022-08-11 | $2.55M derived: sum of 3 quarters · filed 2022-08-11 | $3.04M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $891.00K 10-Q · filed 2022-05-12 | $1.49M derived: sum of 2 quarters · filed 2022-05-12 | $1.97M derived: sum of 3 quarters · filed 2022-05-12 | $2.12M derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $594.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $1.08M derived: sum of 2 quarters · filed 2022-03-14 | $1.23M derived: sum of 3 quarters · filed 2022-03-14 | $1.34M 10-K · filed 2022-03-14 |
| 2020-09-30 | $483.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $636.00K derived: sum of 2 quarters · filed 2021-11-10 | $748.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $153.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $265.00K 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $112.00K 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |